Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture medium for iPS cell culture. This chemically-defined culture medium is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells.

3 Jun 2015

ProBioGen initiates clinical trials of Ebola vaccine using AGE1.CR.pIX cell line

Complex biologics development and manufacturing specialist ProBioGen today announced that an investigational vaccine against Ebola virus disease, produced on its proprietary, continuous muscovy duck AGE1.CR.pIX cell line, has proceeded into clinical trials at the Jenner Institute, Oxford University, UK.

3 Jun 2015

Green Cross Biotherapeutics starts construction on new biopharmaceutical facility in Montreal

This is with great pride that Green Cross Biotherapeutics Inc. kicked off construction today on its biopharmaceutical facility that will be located on the Montreal Technoparc's Saint-Laurent Campus. The CA$315 million project represents one of the largest green field investment projects in Canada in the biopharmaceutical industry, giving place to the construction of the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in Canada.

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today positive preclinical in vivo proof of concept results of GTL002, its multivalent HPV therapeutic vaccine candidate based on the Company’s versatile Vaxiclase platform.

2 Jun 2015

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.

1 Jun 2015

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

1 Jun 2015

Glucose Health Natural Blood Sugar Maintenance product for patients with Type-2 diabetes

Healthcare professionals now have a new OTC (over- the-counter) product designed for the 2 in 5 Americans the Centers for Disease Control and Prevention (CDC) now estimates will develop Type-2 diabetes in their lifetime – Glucose Health Natural Blood Sugar Maintenance.

30 May 2015

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.

30 May 2015

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Arnaud Foussat, VP Research and New Products, TxCell, will deliver two presentations at the 21st Annual Meeting of the International Society of Cellular Therapy, May 27-30, 2015, in Las Vegas, Nevada, US.

30 May 2015

Anything Technologies Media acquires Frontier Indoor Garden Solutions

Anything Technologies Media, Inc. has announced that it has successfully acquired Frontier Indoor Garden Solutions, Inc., a Nevada company focused on the development of commercial indoor medical cannabis facilities and outdoor industrial hemp operations throughout the United States.

29 May 2015

For World No-Tobacco Day WHO makes a stand against illicit tobacco trade

May 31 2015 is World No Tobacco Day and the World Health Organization (WHO) is using this opportunity to bring attention to the illicit trade in tobacco and try to bring an end to it by urging Member States to sign the Protocol to Eliminate the Illicit Trade in Tobacco Products...

29 May 2015

Practical guidance to ensure safe use of flavourings in e-cigarettes

The first practical guide to ensure the safe use of flavourings in e-cigarettes has been published. E-cigarettes and other vaping products contain a nicotine-based liquid that is vapourised and inhaled. There is no combustion so the user inhales vapour, not smoke. This means that e-cigarettes deliver nicotine without smoke toxicants. However, some in the public health community still have expressed concerns over the potential health impacts of flavourings used in e-cigarettes.

29 May 2015

RegenScientific gets FDA approval for Renu Gel injectable implant

RegenScientific announced that it has received FDA-clearance for its Renu Gel injectable implant indicated for vocal fold injection augmentation and today the company commenced shipments of this new product to physicians and hospitals in the United States.

28 May 2015

High Grade Agarose for Nucleic Acid Electrophoresis

CleverGEL is a new environmentally friendly agarose suitable for routine analysis of nucleic acids using standard electrophoretic procedures...

25 May 2015

NIDEK launches GYC-500 Vixi and GYC-500

The GYC-500 Vixi / GYC-500 is a solid state green laser that achieves stable treatment outcomes for multiple applications including, retinal photocoagulation, trabeculoplasty and iridotomy.

25 May 2015

CSL Behring awarded NHF's 2015 Corporate Leadership Award

The National Hemophilia Foundation has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company's longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.

24 May 2015

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow.

21 May 2015

In-house training solutions from PTI: save time and cost in upskilling staff

With course topics that include, but aren’t limited to, business strategy, clinical trials, manufacturing, R&D and regulatory affairs, PTI covers all aspects of the drug and device development lifecycle...

From Pharmaceutical Training International 20 May 2015

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis will combine their unique and proprietary Oligoclonics® and SUREtechnology™ platforms respectively to develop a product combining two bispecific full length IgG antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases...

20 May 2015

Manufacturing News and Research

Further Reading

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

ProBioGen initiates clinical trials of Ebola vaccine using AGE1.CR.pIX cell line

Green Cross Biotherapeutics starts construction on new biopharmaceutical facility in Montreal

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Glucose Health Natural Blood Sugar Maintenance product for patients with Type-2 diabetes

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

Anything Technologies Media acquires Frontier Indoor Garden Solutions

For World No-Tobacco Day WHO makes a stand against illicit tobacco trade

Practical guidance to ensure safe use of flavourings in e-cigarettes

RegenScientific gets FDA approval for Renu Gel injectable implant

High Grade Agarose for Nucleic Acid Electrophoresis

NIDEK launches GYC-500 Vixi and GYC-500

CSL Behring awarded NHF's 2015 Corporate Leadership Award

Nanoparticle-based therapy effective in treating mice with multiple myeloma

In-house training solutions from PTI: save time and cost in upskilling staff

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest Life Science News